Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma
This study elucidates the genomic characteristics of PD-L1-induced resistance to EGFR-TKIs. For patients with concurrent mutations in EGFR and PD-L1 expression, a first-line treatment strategy combining EGFR-TKIs with chemotherapy may offer a more effective alternative.
Authors
- Liangzhong Liu (ORCID: https://orcid.org/0000-0003-0856-7290)
- Zhenzhou Yang (ORCID: https://orcid.org/0000-0003-2496-1992)
- Rongxin Liao
- Xiaoyue Zhang (ORCID: https://orcid.org/0000-0002-9381-8930)
- Fanghao Cai (ORCID: https://orcid.org/0000-0002-6566-5527)
- Xuan Jiang (ORCID: https://orcid.org/0000-0003-2677-2415)
- Guangming Yi
Institutions
- Chongqing University (CN)
- Dalian Medical University (CN)
- Mianyang Third People's Hospital (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Millennium Institute on Immunology and Immunotherapy (CL)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1080/14796694.2024.2435247
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Chongqing Science and Technology Commission
- Chongqing Medical University
- Natural Science Foundation of Chongqing
- Centre Scientifique et Technique du Bâtiment